Brief: Theravance Biopharma Inc Announces Results From Study 0170, A Second Phase 3 Study Of Ampreloxetine, In Patients With Symptomatic Neurogenic Orthostatic Hypotension (nOH)

Theravance Biopharma

04/04/2022 21:08

April 4 (Reuters) - Theravance Biopharma Inc  TBPH.O :
    * THERAVANCE BIOPHARMA, INC. ANNOUNCES RESULTS FROM STUDY
0170, A
SECOND PHASE 3 STUDY OF AMPRELOXETINE, IN PATIENTS WITH
SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH)
    * THERAVANCE BIOPHARMA INC - RESULTS FROM STUDY 0170 SHOW A
BENEFIT IN STUDY PATIENTS WITH MULTIPLE SYSTEM ATROPHY
    * THERAVANCE BIOPHARMA INC - REITERATES PLAN TO BE
SUSTAINABLY
CASH-FLOW POSITIVE BY SECOND HALF OF YEAR
    * THERAVANCE BIOPHARMA INC - PRIMARY ENDPOINT WAS NOT
STATISTICALLY SIGNIFICANT FOR OVERALL POPULATION OF PATIENTS
    * THERAVANCE BIOPHARMA INC - DATA SUGGEST THAT AMPRELOXETINE
WAS
WELL-TOLERATED AND NO NEW SAFETY SIGNALS WERE IDENTIFIED

Source text for Eikon:  ID:nPn37lDCQa 
Further company coverage:  TBPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))